1. Home
  2. KEEL vs NTLA Comparison

KEEL vs NTLA Comparison

Compare KEEL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Keel Infrastructure Corp. Common Stock

KEEL

Keel Infrastructure Corp. Common Stock

N/A

Current Price

$3.33

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.85

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEEL
NTLA
Founded
N/A
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
KEEL
NTLA
Price
$3.33
$12.85
Analyst Decision
Buy
Analyst Count
0
23
Target Price
N/A
$20.02
AVG Volume (30 Days)
35.2M
3.5M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
$229,276,000.00
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
72.03
16.92
52 Week Low
$2.96
$7.95
52 Week High
$7.37
$28.24

Technical Indicators

Market Signals
Indicator
KEEL
NTLA
Relative Strength Index (RSI) 38.58 56.22
Support Level $3.23 $11.55
Resistance Level $3.92 $15.52
Average True Range (ATR) 0.36 0.61
MACD 0.02 0.28
Stochastic Oscillator 23.36 85.61

Price Performance

Historical Comparison
KEEL
NTLA

About KEEL Keel Infrastructure Corp. Common Stock

Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: